# Hour 15: 15:00-15:59 - Sustained High to Evening Transition

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 15 marks the transition from sustained afternoon activity to evening operations. The evening shift begins at 15:00 with SSO-E1 replacing SSO-D1. Surgery P0097 completes successfully at 15:05. A new surgery begins with P0116. One Grade 1 adverse event occurs when P0118 coughs during RT motion-tracking, causing a 2-minute treatment pause.

## Site Status at 15:00

- Total patients on-site: 18
- New arrivals this hour: 8
- Active procedures: 6
- Robot utilization: 48%
- Evening shift change: SSO-E1 on duty

## New Patient Arrivals

| Patient ID | Time | Age | Sex | Cancer Type | Stage | ECOG | Robot |
|-----------|------|-----|-----|-------------|-------|------|-------|
| PAT-ODMND-0116 | 15:05 | 48 | M | Mediastinal tumor | III | 1 | SURG-01 |
| PAT-ODMND-0117 | 15:10 | 32 | F | Forearm sarcoma | I | 0 | COBOT-01 |
| PAT-ODMND-0118 | 15:18 | 67 | M | NSCLC squamous | IIIA | 1 | TRACK-03 |
| PAT-ODMND-0119 | 15:22 | 5 | F | Pediatric ALL | - | 1 | COMPN-02 |
| PAT-ODMND-0120 | 15:30 | 56 | F | Meningioma | I | 0 | RTPOS-03 |
| PAT-ODMND-0121 | 15:38 | 63 | M | HCC | II | 1 | IMAGE-02 |
| PAT-ODMND-0122 | 15:44 | 10 | F | Pediatric osteosarcoma | - | 1 | HUMAN-03, REHAB-03 |
| PAT-ODMND-0123 | 15:52 | 75 | M | Liver mets colorectal | IV | 2 | STEER-02 |

## Completed Procedures

- P0097: Surgery completed at 15:05 (115 min, R0 resection, blood loss 175 mL). Moved to Recovery Bay 5.
- P0117: Cobot biopsy completed at 15:28 (18 min). Sample quality Grade A. Discharged at 15:45.
- P0120: RT positioning completed at 15:55 (25 min). 1.8 Gy delivered, offset 1.1 mm.

## Adverse Events

One Grade 1 adverse event:
- Patient: PAT-ODMND-0118 (67M, NSCLC squamous)
- Time: 15:35
- Event: Cough episode during RT motion-tracking disrupted beam gating
- Severity: Grade 1 (mild)
- Response: Treatment paused for 2 minutes, breathing coaching provided, resumed at 15:37
- Outcome: No dose error. Treatment completed successfully. Fraction delivered as planned.
- Reporting: Documented per ICH E6(R3) Section 2.10 and 21 CFR 312.32

## Investigational Drug Administrations

| Drug | Patient | Dose | Route | Time | IND Protocol |
|------|---------|------|-------|------|-------------|
| Durvalumab | PAT-ODMND-0116 | 10 mg/kg | IV | 15:10 | IND-2026-0089 (pre-op) |
| Ramucirumab | PAT-ODMND-0123 | 8 mg/kg | IV | 15:55 | IND-2026-0045 |

## Regulatory Compliance

### ICH E6(R3) - Section 2.10
Safety event for P0118 documented with complete audit trail including beam gating logs, respiratory monitoring data, and clinical response per Section 2.10.1.

### 21 CFR Part 50 - Section 50.25
Informed consent for P0119 (pediatric ALL, age 5) obtained from parent/guardian per 21 CFR 50 Subpart D pediatric protections. Physical AI system summary reviewed with parent.

### 21 CFR Part 312 - Section 312.32
AE for P0118 documented per safety reporting requirements. Grade 1 event recorded in electronic safety database with robot system logs linked.

## Complementary References

The Unification Standard Level (USL) framework (Kawchak, 2026; DOI: 10.5281/zenodo.18778220) provides complementary robot technical interoperability scoring.

The single-patient cancer journey framework (Kawchak, 2026; DOI: 10.5281/zenodo.19119939) demonstrated autonomous Physical AI trial orchestration for an individual patient. This multi-patient simulation extends that work.
